BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 23, 2004
View Archived Issues
Vertex, Merck Form Potential $384M Cancer Deal For VX-680
In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today)
Read More
Merix, Kirin Collaborating For Personalized Vaccine Products
Read More
CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M
Read More
Momenta's Stock Closes Up After IPO Brings In $34.7M
Read More
Taste Technology Firm Senomyx Goes Public With $36M Offering
Read More
Other News To Note
Read More